Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): Results of a multicentre randomized phase II trial

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 1, 2007, Pages 143-150

  Binder, D ^a   Schweisfurth, H ^b   Grah, C ^c   Schaper C ^a   Temmesfeld Wollbruck B ^a   Siebert, G ^a   Suttorp, N ^a   Beinert, T ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CARL THIEM KLINIKUM   (Germany)

^c Medizinische Klinik m S Kardiologie   (Germany)

^d Klinik Wartenberg   (Germany)

Author keywords

Chemotherapy; Non small cell lung cancer; Randomized phase II study; Sequential therapy design

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; TAXOIDS; TREATMENT OUTCOME; VOMITING;

EID: 34247338453     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0358-7     Document Type: Article

References (26)

1. Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jimenez U, Gonzalez-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ, de las Penas R, Felip E, Lopez-Vivanco G; Spanish Lung Cancer Group (2003) Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21:3207-3213
2. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488
3. Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S (2005) Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 68:382-390
4. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292:470-484
5. Dongiovanni D, Fissore C, Berruti A, Buffoni L, Addeo A, Barone C, Polimeni MA, Ottaviani D, Bertetto O, Dongiovanni V (2005) Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study. Lung Cancer 47:269-275
6. Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K (1999) Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10:943-947
7. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D (2001) Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92:146-152
8. Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR (2004) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022-5026
9. Feliu J, Martin G, Lizon J, Chacon JI, Dorta J, de Castro J, Rodriguez A, Sanchez Heras B, Torrego JC, Espinosa E, Gonzalez Baron M; Oncopaz Cooperative Group, Spain (2001) Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study. Ann Oncol 12:1369-1374
10. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B et al (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651
11. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024
12. Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G; Gruppo Ocologico Italia Meridionale (2003) Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 39:179-189
13. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937-2945
14. Grossi F, Belvedere O, Fasola G, Barbone F, Rizzato S, Sibau A, Recchia L, Vigevani E, Ceschia T, Morelli A, Guglielmi A, Puglisi F, Follador A, Talmassons G, Sobrero AF (2004) Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer 46:99-106
15. Hosoe S, Komuta K, Shibata K, Harada H, Iwamoto Y, Ohsaki Y, Morioka T, Origasa H, Fukushima M, Furuse K, Kawahara M (2003) Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer 88:342-347
16. Janssen-Heijnen ML, Coebergh JW (2001) Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 31:123-137
17. Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with nonsmall cell lung cancer: results of a dose-finding study. Lung Cancer 44:363-368
18. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
19. Pallis AG, Agelidou A, Papakotoulas P, Tsaroucha A, Agelidou M, Agelaki S, Androulakis N, Vamvakas L, Gerogianni A, Kotsakis A, Kentepozidis N, Georgoulias V (2006) A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer 52:165-171
20. Perol M, Lena H, Thomas P, Robinet G, Fournel P, Coste E, Belleguic C, Le Caer H, Blanchon F, Vergnenegre A, Vernejoux JM, Schuller-Lebeau MP, Pham E (2002) Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study. Ann Oncol 13:742-747
21. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morere JF, Milleron B, Debieuvre D, Castera D, Souquet PJ, Moro-Sibilot D, Lemarie E, Kessler R, Janicot H, Braun D, Spaeth D, Quantin X, Clary C (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602-610
22. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M; Italian Lung Cancer Project (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291
23. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
24. Shepherd FA (2004) Current paradigms in first-line treatment of non-small-cell lung cancer. Oncology (Williston Park) 18(Suppl5):13-20
25. Spiridonidis CH, Laufman LR, Carman L, Moore T, Blair S, Jones J, George C, Patel T, Roach R, Rupert R, Zangmeister J, Colborn D, Kuebler JP (2001) Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 12:89-94
26. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128:452-462